clinic
trial
hivinfect
patient
receiv
iv
infus
mismatch
doublestrand
rna
dose
level
frequent
advers
event
flush
chill
fever
tight
chest
dyspnoea
flulik
symptom
nausea
reaction
selflimit
gener
subsid
infus
complet
infus
usual
accompani
transient
leucopenia
leucocytosi
one
patient
receiv
mismatch
doublestrand
rna
discontinu
therapi
develop
flulik
symptom
fatigu
combin
therapi
zidovudin
toxic
similar
caus
zidovudin
alon
studi
compar
placebo
zidovudin
recipi
total
number
advers
event
differ
significantli
treatment
group
patient
undergo
structur
treatment
interrupt
sti
haart
advers
event
associ
mild
selflimit
incid
insulin
resist
hyperlipidaemia
advers
chang
lactic
acid
level
common
advers
event
clinic
trial
metastat
melanoma
patient
includ
myalgia
headach
fatigu
mismatch
doublestrand
rna
synergist
multipl
antihiv
drug
combin
indic
determin
antihiv
agent
alon
combin
mismatch
doublestrand
rna
use
doseeffect
analys
calcusyn
window
softwar
mismatch
doublestrand
rna
synergist
combin
abacavir
zidovudin
zalcitabin
didanosin
stavudin
efavirenz
indinavir
ritonavir
nelfinavir
amprenavir
synergist
antagonist
lamivudin
delavirdin
nevirapin
saquinavir
preclin
studi
reduc
serum
liver
viral
dna
level
duck
congenit
infect
duck
hepat
b
viru
least
addit
effect
ganciclovir
effect
circul
duck
hbsag
viral
replic
return
baselin
level
treatment
discontinu
clinic
studi
effect
mismatch
doublestrand
rna
immun
function
compar
placebo
randomis
doubleblind
crossov
studi
actg
volunt
overal
signific
differ
two
treatment
term
product
interferon
biolog
marker
interferon
lymphocyt
function
lymphocyt
prolif
respons
natur
killer
cell
activ
symptom
score
greater
mismatch
doublestrand
rna
recipi
placebo
recipi
symptom
mild
natur
betweengroup
differ
signific
day
dose
patient
chronic
fatigu
syndrom
normalis
upregul
synthetasernas
l
system
clear
human
herpesviru
antigenposit
cell
peripher
blood
mononuclear
cell
cultur
hivinfect
mismatch
doublestrand
rna
induc
express
physiolog
function
antivir
protect
system
synthetasernas
l
system
cell
vitro
inhibit
hivrel
reduct
cell
growth
rate
act
synergist
revers
transcriptas
inhibitor
antisens
oligonucleotid
direct
tat
gene
display
synerg
hiv
vitro
use
combin
didanosin
contrast
synerg
demonstr
zidovudin
combin
ratio
rang
also
act
synergist
zidovudin
zidovudineresist
strain
compound
shown
inhibit
human
herp
infect
lymphocyt
concentr
also
activ
rotaviru
mismatch
doublestrand
rna
equal
activ
wildtyp
hiv
hiv
resist
nevirapin
proteas
inhibitor
nucleosid
revers
trancriptas
inhibitor
melanoma
ten
patient
metastat
melanoma
treat
mismatch
doublestrand
rna
openlabel
phase
iii
trial
drug
administ
iv
low
dose
one
patient
high
dose
nine
patient
minut
twice
weekli
week
two
patient
receiv
highdos
therapi
achiev
complet
respons
receiv
mainten
therapi
least
month
follow
remain
complet
respons
without
therapi
month
mismatch
doublestrand
rna
well
toler
chronic
fatigu
syndrom
significantli
improv
patient
physic
perform
assess
treadmil
exercis
toler
test
ett
placebocontrol
phase
iii
studi
patient
sever
debilit
chronic
fatigu
syndrom
ampligen
twice
weekli
superior
placebo
improv
ett
vs
patient
popul
complet
week
treatment
also
intenttotreat
popul
vs
complet
week
treatment
randomis
placebocontrol
trial
therapi
improv
physic
cognit
perform
patient
chronic
fatigu
syndrom
condit
possibl
viral
aetiolog
belgium
studi
patient
chronic
fatigu
syndrom
randomis
receiv
mismatch
doublestrand
rna
twice
weekli
placebo
week
mismatch
doublestrand
rna
significantli
improv
cognit
physic
perform
physic
perform
activ
daili
live
measur
use
karnofski
perform
score
show
improv
baselin
exercis
perform
measur
bicycl
test
oxygen
uptak
improv
lmin
baselin
lmin
treatment
mismatch
doublestrand
rna
cognit
improv
seen
patient
receiv
mismatch
doublestrand
rna
measur
use
cognit
subscal
scl
neuropsycholog
function
test
significantli
greater
improv
seen
patient
receiv
mismatch
doublestrand
rna
compar
placebo
mismatch
doublestrand
rna
gener
well
toler
accord
media
releas
patient
treat
mismatch
doublestrand
rna
experienc
appar
complet
clinic
recoveri
month
treatment
spontan
improv
untreat
patient
chronic
fatigu
syndrom
hepat
b
result
phase
iii
studi
mismatch
doublestrand
rna
two
three
timesweek
eight
patient
chronic
hepat
b
indic
drug
may
antivir
effect
four
patient
lost
hbv
dna
three
patient
becam
hbeag
seroneg
week
treatment
none
patient
relaps
result
phase
studi
actg
unabl
confirm
previou
benefici
effect
mismatch
doublestrand
rna
hiv
infect
thirtynin
hivinfect
patient
asymptomat
diseas
earli
arc
receiv
one
six
dose
mismatch
doublestrand
rna
week
mismatch
doublestrand
rna
signific
effect
antigenaemia
hiv
viraemia
number
hivinfect
cell
howev
rate
cell
deplet
reduc
effect
dosedepend
addit
patient
develop
opportunist
infect
new
hivassoci
symptom
receiv
mismatch
doublestrand
rna
patient
least
month
previou
zidovudin
treatment
therapi
administ
prior
develop
advanc
stage
symptom
associ
higher
count
increas
immun
function
compar
untreat
patient
thu
appear
activ
zidovudineresist
hiv
strain
studi
conduct
zidovudinetr
patient
mismatch
doublestrand
rna
therapi
effect
initi
earlier
cours
hiv
diseas
studi
period
patient
treat
twice
weekli
mean
decreas
count
compar
placebo
recipi
patient
baselin
count
show
mean
increas
count
peak
week
placebo
recipi
consist
decreas
baselin
chang
therapi
week
placebo
treatment
revers
declin
seven
patient
recipi
like
exhibit
delayedtyp
hypersensit
respons
less
like
progress
aid
placebo
recipi
significantli
fewer
patient
relaps
within
first
day
structur
treatment
interrupt
sti
treat
phase
iib
studi
primari
endpoint
mean
total
time
haartfre
interv
rebound
plasma
rna
two
group
patient
harvard
cohort
eight
newlyacut
hivinfect
patient
studi
group
design
similar
referenc
harvard
cohort
similar
haart
given
month
b
cellsml
c
hiv
rna
level
copiesml
main
differ
group
harvard
cohort
studi
within
week
month
initi
infect
wherea
studi
group
infect
hiv
sever
year
interim
data
analysi
perform
control
treat
group
obtain
scientif
literatur
metaanalysi
second
concurr
control
group
obtain
ident
particip
medic
institut
metaanalysi
none
patient
relaps
within
first
day
compar
control
group
patient
p
second
analysi
median
durat
sti
group
week
compar
week
concurr
control
group
phase
iib
studi
amp
patient
hiv
undergo
three
structur
treatment
interrupt
sti
haart
iv
twice
weekli
therapi
result
signific
prolong
control
hiv
viraemia
compar
untreat
control
patient
taken
haart
given
n
continu
show
viru
level
copiesml
mean
week
count
control
group
patient
n
taken
haart
given
develop
hiv
rebound
within
mean
week
addit
group
demonstr
increas
cell
suggest
induct
immunogen
